TY  - JOUR
AU  - Heidegger, Isabel
AU  - Kesch, Claudia
AU  - Kretschmer, Alexander
AU  - Tsaur, Igor
AU  - Ceci, Francesco
AU  - Valerio, Massimo
AU  - Tilki, Derya
AU  - Marra, Giancarlo
AU  - Preisser, Felix
AU  - Fankhauser, Christian D
AU  - Zattoni, Fabio
AU  - Chiu, Peter
AU  - Puche-Sanz, Ignacio
AU  - Olivier, Jonathan
AU  - van den Bergh, Roderik C N
AU  - Kasivisvanathan, Veeru
AU  - Pircher, Andreas
AU  - Virgolini, Irene
AU  - Gandaglia, Giorgio
PY  - 2022
DO  - 10.1177/17588359221081922
SN  - 1758-8340
UR  - http://hdl.handle.net/10668/20229
T2  - Therapeutic advances in medical oncology
AB  - Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select...
LA  - en
PB  - Sage Publications Ltd.
KW  - 177Lu-PSMA-617 radioligand therapy
KW  - biomarkers
KW  - mCRPC
TI  - Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.
TY  - research article
VL  - 14
ER  -